(913) 307-1000                    
(Registrant's telephone number, including area code)

                                                                                               
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes  [_]  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of October 16, 2003, there were 7,379,395 shares of Common Stock, $0.10 par value, of the registrant outstanding.

See Notes to Unaudited Condensed Consolidated Financial Statements.

See Notes to Unaudited Condensed Consolidated Financial Statements.

The results of operations for the three months ended September 30, 2003 are not necessarily indicative of the results to be expected for the entire fiscal year.

Basic earnings per share have been computed using the weighted average number of shares of common stock, par value $0.10 ("Common Stock"), of the Company outstanding for each period presented. For the three months ended September 30, 2003 and September 30, 2002, the dilutive effect of stock options and other common stock equivalents is included in the calculation of diluted earnings per share using the treasury stock method.

On October 11, 2000, Fratelli Auriana, Inc., an entity controlled by Mr. Lawrence Auriana, the Chairman of the Board of the Company and holder of more than 5% of the Company's outstanding Common Stock, committed to loan the Company up to $2,000,000, in addition to amounts previously loaned to the Company, to be drawn in multiples of $250,000, as needed by the Company. Conditions were finalized and a Loan Agreement was signed December 1, 2000 between Fratelli Auriana, Inc. and the Company. On September 17, 2003, the Company and Fratelli Auriana, Inc. entered into a Third Amendment to the Loan Agreement between the two parties, extending the maturity date to September 30, 2005. As of October 17, 2003, the Company has not borrowed against this loan agreement.

The Company accounts for stock-based employee and outside directors compensation under Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations. The Company has adopted the disclosure-only provisions of Statement of Financial Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based Compensation" and SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure", which was released in December 2002 as an amendment of SFAS No. 123. The following table illustrates the effect on net income and earnings per share if the fair value based method had been applied to all awards.

The weighted average fair value at date of grant for options granted during the three months ended September 30, 2003 and 2002 were $10.085 and $8.076 per option, respectively. The fair value of options at date of grant was estimated using the Black-Scholes option pricing model utilizing the following assumptions:

To The Board of Directors and Stockholders of
Mediware Information Systems, Inc.

Eisner LLP
New York, New York
October 22, 2003

Total revenues for the quarter ended September 30, 2003 were $9,011,000, an increase of $1,025,000 or 12.8% from the same period a year ago. The change in revenues reflects quarter over quarter increases of $1,652,000 or 69.6% in the Blood Bank Division; $313,000 or 118.6% in the Operating Room Division; and $64,000 or 11.8% in the JAC Division. These increases were partially offset by a $1,004,000 or 20.9% decrease in total revenues in the Pharmacy Division.

System sales, which include proprietary software, third party software and hardware sales, for the first quarter of fiscal 2004 were $2,738,000, a decrease of $688,000 or 20.1% from the first quarter last year. The Operating Room Division reported system sales of $194,000 in the fiscal year 2004 first quarter compared to none in the same period of last year while the JAC Division experienced an increase in system sales to $160,000 compared to $155,000 in fiscal year 2004 and 2003 first quarters, respectively. The Pharmacy Division reported system sales of $1,110,000, a $1,815,000 or 62.1% decrease compared to $2,925,000 in fiscal 2003. Prior year Pharmacy system sales reflect two significant Integrated Delivery Network contracts signed during that period which represent the primary reason for the quarter over quarter sales variance. During the current fiscal year quarter, the Pharmacy Division successfully released and subsequently signed its initial contract for its MediCOEä product, a Clinician Order Entry application. MediCOE allows clinicians to enter medication orders and manage drug therapy directly into the Pharmacy Division's WORxä product using internet technology. Management believes, but cannot assure, that customer acceptance of WORx and related products such as MediCOE will continue to be positive. The Blood Bank Division experienced an increase in system sales of $928,000 or 268.2% to $1,274,000 during the first quarter of fiscal year 2004 compared to $346,000 in the same period a year ago. The increase in Blood Bank system sales is the result of sales of its new transfusion blood bank software solution, HCLLä , initially released during the fourth quarter of fiscal 2003. Management believes, but cannot assure, that system sales for the Blood Bank Division will continue to increase as a result of its continued marketing efforts for the new HCLL product.

Service revenues, which include recurring software support, implementation, training and validation services, were $6,273,000 during the first quarter of fiscal 2004, an increase of $1,713,000 or 37.6%, compared to $4,560,000 during the same period a year ago. All Divisions had increased service revenues compared to the first quarter of fiscal year 2003, reflecting a rise in implementation and installation activities primarily related to system sales completed during the previous fiscal year as well as an increase of annual support fees generated from new customers joining the Company's installed base. In addition, the Blood Bank Division continued to provide services to assist customers with their FDA required validation processes identified during the last half of fiscal year 2003. The rise in service revenues includes increases of $811,000 or 43.1% in the Pharmacy Division; $724,000 or 35.7% in the Blood Bank Division; $119,000 or 45.1% in the Operating Room Division; and $59,000 or 15.2% in the JAC Division. Management believes, but cannot give any assurance, that as system sales increase, corresponding service revenues should also increase.

Cost of systems includes the cost of computer hardware and sublicensed software purchased from computer and software manufacturers as part of a complete system offering and excludes amortization of capitalized software. Cost of systems decreased to $491,000 during the quarter ended September 30, 2003, from $592,000 in the same period a year ago primarily due to the reduction in system sales in the Pharmacy Division. As a percentage of new systems sales, cost of systems was 17.9% and 17.3% during the quarters ended September 30, 2003 and 2002, respectively. These costs can fluctuate as the mix of revenue varies between high margin proprietary software and lower margin computer hardware and sublicensed software components.

Cost of services includes the salaries of client service personnel and communications expenses along with the direct expenses of the client service function. Cost of services increased $248,000 or 16.5% to $1,747,000 in the first quarter of fiscal 2004 as compared to the same period a year ago. The increase in cost of services is primarily attributed to increases in system implementations associated with the Company's WORx Pharmacy System as well as validation support efforts within the Blood Bank Division. An increase in implementation of extended service activities, which typically results in higher gross margin, as a proportion of total service revenues, resulted in an increase in service revenue gross margin to 72.2% during the first three months of fiscal 2004 compared to 67.1% in same period of fiscal year 2003. Management believes, but cannot assure, that demand for its contracted services will continue to be strong and cannot assure that cost of services as a percentage of serv ice revenue will remain consistent with its current utilization rates.

Amortization of capitalized software increased $399,000 or 86.7%, to $859,000 in the first quarter of fiscal 2004 compared to $460,000 in the same period of 2003. This increase is primarily due to increased amortization of capitalized software costs related to the Blood Bank Division's new transfusion product (HCLL) which reached commercialization in the fourth quarter of fiscal 2003 as well as amortization of capitalized software costs related to the MediCOE product released by the Pharmacy Division during the current quarter.

Selling, general and administrative ("SG&A") expenses include marketing and sales salaries, commissions, travel and advertising expenses. Also included is bad debt expense; legal, accounting and professional fees; salaries and bonus expenses for corporate, divisional, financial and administrative staffs; utilities, rent, communications and other office expenses; and other related direct administrative expenses. SG&A for the quarter ended September 30, 2003 was $3,282,000, an increase of $75,000 or 2.3%, compared to $3,207,000 in the first quarter of fiscal 2003. This increase reflects a rise in general business and medical insurance expenses as well as additional costs associated with Sarbanes-Oxley compliance activities.

Net income was $1,198,000 for the quarter ended September 30, 2003, an increase of $276,000 or 29.9% as compared to net income of $922,000 in the quarter ended September 30, 2002.

As of September 30, 2003, the Company had cash and cash equivalents of $7,651,000 compared to cash and cash equivalents of $7,525,000 at June 30, 2003. At September 30, 2003, working capital was $5,834,000 and the current ratio was 1.52:1 compared to $4,241,000 and 1.37:1 at June 30, 2003. Cash provided by operating activities was $1,602,000 during the first quarter of fiscal year 2004 compared to $2,031,000 during the same period a year ago. The decreased cash provided by operating activities is primarily due to an increase in accounts receivable reflecting the rise in revenues.

The Company invested $1,554,000 and $1,424,000 during the three months ended September 30, 2003 and 2002, respectively, primarily related to the Company's ongoing investment in software development projects. Of amounts invested, the Company capitalized $1,384,000 and $1,217,000 of product development costs during the three months ended September 30, 2003 and 2002, respectively.

For the three months ended September 30, 2003, the Company received $77,000 related to proceeds from the exercise of options, compared to $177,000 generated in the same period a year ago.

The Company's liquidity is influenced by its ability to perform on a "best of breed" basis in a competitive industry that is currently impacted by consolidations of healthcare information system providers. The factors that may affect liquidity are the Company's ability to penetrate the market for its products, maintain or reduce the length of the selling cycle, and collect cash from clients as systems are implemented. Exclusive of activities involving any future acquisitions of products or companies that complement or augment the Company's existing line of products, management believes that current available funds, cash generated from operations and a $2,000,000 line of credit from Fratelli Auriana, Inc. will provide sufficient liquidity to meet operating requirements for the foreseeable future. The Company continues to review its long-term cash needs and investment options. As of October 20, 2003, the Company has not borrowed against the line of credit. Currently, there are no plans f or additional outside financing.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to the Company.

New Accounting Pronouncements

None.

The Company does not currently have any material exposure to foreign currency transaction gains or losses. However, the Company does have some exposure to foreign currency rate fluctuations arising from sales made to customers in the United Kingdom. These transactions are made by the Company's U.K. based, wholly owned subsidiary which transacts business in the local functional currency. To date, the Company has not entered into any derivative financial instrument to manage foreign currency risk and is currently not evaluating the future use of any such financial instruments.

The Company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 240.13a-14(c) and 15d-14(c) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of a date within ninety days prior to the filing date of this quarterly report. Based on that review and evaluation, which included inquiries made to certain other employees of the Company, the CEO and CFO have concluded that the Company's current disclosure controls and procedures, as designed and implemented, are reasonably adequate to ensure that they are provided with material information relating to the Company required to be disclosed in the reports the Company files or submits under the Exchange Act. There have not been any significant changes in the Company's internal controls or in other factors that could significantly affect the se controls subsequent to the date of their evaluation. There were no significant deficiencies or material weaknesses identified, and therefore no corrective actions were taken.

(b).     Reports on Form 8-K

On August 28, 2003, a Form 8-K was filed by the Company under "Item 9. Regulation FD Disclosure."

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


                                                   MEDIWARE INFORMATION SYSTEMS, INC.
                                                                       (Registrant)

October 27, 2003                       /s/   GEORGE J. BARRY                    
          Date                                        GEORGE J. BARRY
                                                          PRESIDENT AND CHIEF EXECUTIVE OFFICER

October 27, 2003                      /s/   JILL H. SUPPES                          
          Date                                       JILL H. SUPPES
                                                         CHIEF FINANCIAL OFFICER

EXHIBIT 15

To the Board of Directors and Stockholders of
Mediware Information Systems, Inc.

We have reviewed, in accordance with standards established by the American Institute of Certified Public Accountants, the unaudited interim condensed consolidated financial statements of Mediware Information Systems, Inc. and subsidiaries as of September 30, 2003 and for the three month periods ended September 30, 2003 and 2002, as indicated in our review report dated October 22, 2003; because we did not perform an audit, we expressed no opinion on those financial statements.

We are aware that our review report, which is included in your Quarterly Report on Form 10-Q for the quarter ended September 30, 2003, is incorporated by reference in the Registration Statements on Form S-8 (No. 333-07591 and No. 333-83016).

We are also aware that our review report, pursuant to Rule 436(c) under the Securities Act of 1933, is not considered a part of the Registration Statement prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Section 7 and 11 of that Act.

Eisner LLP

New York, New York
October 22, 2003

A signed original of this written statement required by Section 906, or other authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Mediware Information Systems, Inc. and will be retained by Mediware Information Systems, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.